Drugs / WT1 mRNA-loaded DCs
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04911621 | Sep 2021 → Aug 2025 | diffuse intrinsic pontine glioma, high grade astrocytic tumor | University Hospital, Antwerp | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT1 mRNA-loaded DCs | “intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks” NCT04911621 ↗ |
| Known as | WT1/DC | “assessing the feasibility and safety of WT1 mRNA-loaded DC (WT1/DC) immunotherapy in combination with conventional treatment in pHGG and DIPG” PMID 38503417 ↗ Mar 2024 |
| Modality | Cell therapy | “the manufacturing of autologous WT1/DC vaccines” PMID 38503417 ↗ Mar 2024 |